PubMed · 1998 · 24 citations · 46 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesT Cell Responses To TumorsTumor AntigensTumor-associated AntigensAntitumor Immune ActivationImmunogenicity Of Tumor AntigensMelanoma ImmunotherapyMelanoma-associated AntigensMhc Class I MoleculesT-cell Responses To Tumor AntigensTumor Antigen ImmunogenicityTumor Immunogenicity
Tumor-associated Ags (TAA) that characterize a population of malignant cells are recognized by CTLs in the context of determinants specified by the MHC class I locus. Nevertheless, most progressively growing neoplasms do not induce antitumor immune responses that can control tumor cell growth. The TAA may be insufficiently antigenic. We found previously that immunization of mice with a cellular immunogen prepared by transfecting tumor DNA into allogeneic mouse fibroblasts resulted in strong antitumor immune responses that were specific for the type of tumor from which the DNA was obtained. Since the fibroblasts differed at the MHC from the immunized mice, we postulated that the immunogenic properties of the allogeneic transfected cells might be enhanced if the cells were modified to express syngeneic class I determinants. In a mouse melanoma model system, the H-2Kb gene was introduced into LM mouse fibroblasts (H-2k). Afterward, the cells were transfected with DNA from B16 melanoma cells (H-2b). The transfected cells were tested for their immunotherapeutic properties in C57BL/6J mice (H-2b) with melanoma. Mice with melanoma treated solely by immunization with the semiallogeneic transfected cells developed strong, long-term resistance to the growth of the tumor. In some instances, the mice survived indefinitely. Intact rather than disrupted transfected cells were required to induce the antimelanoma response, consistent with direct presentation of TAA by the transfected cells. The augmented resistance to melanoma in mice treated with the semiallogeneic transfected cells points toward an analogous form of therapy for cancer patients.
46
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Lawrence A. Donehower, Michele Harvey, Betty L. Slagle et al. · Nature · 1992 · 4.7K citations
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
Pierre van der Bruggen, Catia Traversari, Patrick Chomez et al. · Science · 1991 · 3.5K citations
Life Sciences, Immunology, Oncology +17
T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
Steven Gillis, Mary M. Ferm, Winny Ou et al. · The Journal of Immunology · 1978 · 3.3K citations · Full text
Glen Dranoff, Elizabeth M. Jaffee, A Lazenby et al. · Proceedings of the National Academy of Sciences · 1993 · 2.8K citations
Medicine, Immunology, Oncology +17
Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor
Michael Wigler, Àngel Pellicer, Saul J. Silverstein et al. · Cell · 1978 · 1.3K citations